Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 921, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2022.174889
Keywords
Nuclear factor of activated T cells; Hematological malignancies; Target therapy; T cells immunity
Categories
Funding
- National Natural Science Foundation of China [81770152, 82070152, 81770158]
- Guangdong Basic and Applied Basic Research Foundation [2021A1515110004]
- China postdoctoral science foundation [2021M701427]
Ask authors/readers for more resources
The NFAT family plays a crucial role in immune response and has been found to be altered in hematological malignancies. Therapeutically targeting NFAT in the treatment of these malignancies could be a promising strategy.
The nuclear factor of activated T cells (NFAT) family is well known for the survival of hemopoietic cells and plays an important role in the immune response. In recent decades, NFAT alteration was discovered in hematological malignancies, suggesting that targeted NFAT therapy may be a promising strategy for the treatment of hematological malignancies. In this review, we present an overview of the NFAT signaling pathway in lymphocytes as well as aberrant NFAT in hematological malignancies. Moreover, therapeutically targeting NFAT in hematological malignancies is also discussed in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
